Completed PHASE2 INTERVENTIONAL 2-arm NCT03150966

The Immunomodulatory Effects of Oral Nanocurcumin in Multiple Sclerosis Patients

The Effects of Oral Nanocurcumin on Expression Levels of microRNAs and Treg Cells and Th17 Cells Development Factors in Multiple Sclerosis Patients

Sponsor: Tabriz University of Medical Sciences

Conditions Multiple Sclerosis

Interventions Nanocurcumin Placebo

Updated 8 times since 2017 Last updated: Sep 13, 2018 Started: Jun 8, 2016 Primary completion: Aug 10, 2017 Completion: Nov 7, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Multiple Sclerosis and is currently completed. Tabriz University of Medical Sciences leads this study, which shows 8 recorded versions since 2016 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Oct 2018 — Jan 2021 [monthly]

Completed PHASE2

Status: Recruiting → Completed

▶ Show 3 earlier versions

Jun 2018 — Oct 2018 [monthly]

Recruiting PHASE2
Oct 2017 — Jun 2018 [monthly]

Recruiting PHASE2
Jun 2017 — Oct 2017 [monthly]

Recruiting PHASE2

First recorded

Jun 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Tabriz University of Medical Sciences

Data source: Tabriz University of Medical Sciences

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tabriz, Iran